Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

NEDDylated-Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors (ChIP-Seq)

ABSTRACT: NEDDylated-Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors (ChIP-Seq)

PROVIDER: PRJNA875475 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR21381054.fastq.gz	Fastqsanger.gz
	SRR21381055.fastq.gz	Fastqsanger.gz
	SRR21381056.fastq.gz	Fastqsanger.gz
	SRR21381057.fastq.gz	Fastqsanger.gz
	SRR21381058.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

NEDDylated-Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors

Project description:NEDDylated-Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors

| PRJNA875473 | ENA

NEDDylated-Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors (RNA-Seq)

Project description:DNA topoisomerase 1 (Top1) inhibitors are mainstays of anticancer therapy. These drugs trap Top1 on DNA, stabilizing the Top1-cleavage complex (Top1-cc). The accumulation of Top1-ccs perturbs DNA replication fork progression, leading to DNA breaks and cell death. By analyzing the genomic occupancy and activity of Top1, we show that cells adapt to treatment with multiple doses of Top1 inhibitor by promoting the degradation of Top1-ccs, allowing cells to better tolerate subsequent doses of Top1 inhibitor. The E3-RING Cullin 3 Ligase in complex with the BTBD1 and BTBD2 adaptor proteins promote Top1-cc ubiquitination and subsequent proteasomal degradation. NEDDylation of Cullin 3 activates this pathway and inhibition of protein NEDDylation or depletion of Cullin 3 sensitizes cancer cells to Top1 inhibitors. Collectively, our data identify a novel NEDD8-Cullin 3 pathway involved in the adaptive response to Top1 inhibitors, which can be targeted to improve the efficacy of Top1 drugs in cancer therapy.

2022-11-04 | GSE212469 | GEO

NEDDylated-Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors (ChIP-Seq)

2022-11-04 | GSE212468 | GEO

NEDDylated-Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors (RNA-Seq)

Project description:NEDDylated-Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors (RNA-Seq)

| PRJNA875478 | ENA

NEDDylated Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors.

Project description:DNA topoisomerase 1 (TOP11) inhibitors are mainstays of anticancer therapy. These drugs trap TOP1 on DNA, stabilizing the TOP1-cleavage complex (TOP1-cc). The accumulation of TOP1-ccs perturbs DNA replication fork progression, leading to DNA breaks and cell death. By analyzing the genomic occupancy and activity of TOP1, we show that cells adapt to treatment with multiple doses of TOP1 inhibitor by promoting the degradation of TOP1-ccs, allowing cells to better tolerate subsequent doses of TOP1 inhibitor. The E3-RING Cullin 3 ligase in complex with the BTBD1 and BTBD2 adaptor proteins promotes TOP1-cc ubiquitination and subsequent proteasomal degradation. NEDDylation of Cullin 3 activates this pathway, and inhibition of protein NEDDylation or depletion of Cullin 3 sensitizes cancer cells to TOP1 inhibitors. Collectively, our data uncover a previously unidentified NEDD8-Cullin 3 pathway involved in the adaptive response to TOP1 inhibitors, which can be targeted to improve the efficacy of TOP1 drugs in cancer therapy.

| S-EPMC9733930 | biostudies-literature

NEDDylated-Cullin 3 mediates the adaptive response to topoisomerase 1 inhibitors

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-11-04 | GSE212470 | GEO

Topoisomerase II inhibitors and histone eviction

Project description:Topoisomerase II inhibitors and histone eviction

| PRJNA148617 | ENA

RNA helicase DDX5 mediates adaptive response to multi-kinase inhibitors in liver cancer

Project description:RNA helicase DDX5 mediates adaptive response to multi-kinase inhibitors in liver cancer

| PRJNA818332 | ENA

Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer

Project description:Enhancer reactivation mediates adaptive resistance to FGFR inhibitors in triple-negative breast cancer